Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Cash (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Change in Cash for 6 consecutive years, with -$2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 96.18% year-over-year to -$2.4 million, compared with a TTM value of -$7.9 million through Dec 2025, up 88.54%, and an annual FY2025 reading of -$7.9 million, up 88.54% over the prior year.
  • Change in Cash was -$2.4 million for Q4 2025 at Cytek Biosciences, down from $17.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $409.2 million in Q4 2021 and bottomed at -$204.4 million in Q3 2021.
  • Average Change in Cash over 5 years is -$3.8 million, with a median of -$2.9 million recorded in 2025.
  • The sharpest move saw Change in Cash crashed 99313.11% in 2021, then soared 1132.59% in 2024.
  • Year by year, Change in Cash stood at $409.2 million in 2021, then tumbled by 110.27% to -$42.0 million in 2022, then skyrocketed by 109.52% to $4.0 million in 2023, then crashed by 1688.55% to -$63.6 million in 2024, then surged by 96.18% to -$2.4 million in 2025.
  • Business Quant data shows Change in Cash for CTKB at -$2.4 million in Q4 2025, $17.8 million in Q3 2025, and -$19.8 million in Q2 2025.